Solid stock: buy or sell?

SLDB stock price: $6.09 4.82% At close on May 21st, 2019

Updated on:
May 21st, 2019


Solid climbed a super good 4.82% and closed at $6.09. On Wednesday SLDB collapsed a scary -6.94%.

Solid Biosciences, LLC engages in identifying and developing gene therapies for duchenne muscular dystrophy in the United States.

Should I buy Solid stock?

Trading stocks requires experience and discipline, and your buying and selling decisions must come following a methodology. That's why is so important to define your own trading plan that matches with your character as inversor. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

None of our preferred buy setups matches with Solid stock situation right now, therefore this is not a suitable entry point.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This is not a selling recommendation at all, just it's not the best moment to buy if you follow any of these trading strategies.

Is Solid Biosciences stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. At, we gathered 5 ratings published for SLDB stock in the last 30 days.

The general sentiment of these ratings is bearish for SLDB stock, with 2 negative ratings.
Is SLDB a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-5-14Goldman Sachs GroupNeutralSell
2019-5-14Credit Suisse GroupNeutralUnderperform
2019-2-8Svb LeerinkOutperformMarket Perform
2019-2-7Chardan Capitaln/aBuy

Solid stock analysis

Daily outlook

Shares of Solid Biosciences closed today at $6.09 and climbed a super good 4.82%.

Shares of Solid Biosciences closed today at $6.09 and climbed a super good 4.82%.

SLDB stock chart (daily)

Weekly outlook

After sliding a scary -51.99% in a week last week, Solid closed this week at $6.09 and stepped up a slightly fine 0.83%.

Far behind is the all-time high Solid Biosciences marked by mid June 2018 and since then the price is -88.89% below that top.

SLDB stock chart (weekly)

Solid stock price history

Solid IPO was on January 26th, 2018 at $25.50 per share1. Since then, SLDB stock declined a -76.10%, with a yearly average of -76.10%.

1: Adjusted price after possible price splits or reverse-splits.

Solid stock historical price chart

SLDB stock reached all-time highs on June with a price of $54.84.

Solid stock price target is $10.50

Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. We found 2 price forecasts for Solid stock posted in the last month:
SLDB stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-5-14Credit Suisse GroupDowngrades$7.00$6.00-14.3%
2019-2-7Chardan CapitalReiteratesn/a$15.00-
(in average)$7.00$10.5050.0%
The price forecast for Solid Biosciences stock is $10.50, moving in a range between $15.00 and $6.00. In average, analysts' outlook on SLDB price target is positive, increasing the forecast by a 50.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Solid Biosciences reported very good results for 2018-Q4 on March. Solid Biosciences jumped Earnings per Share (EPS) by 15.50%, beating experts consensus of $-0.58. Solid Biosciences posted $-0.67.
SLDB earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to , last anual turnover report draw of to M dollars. , its income margin (compared to sales) to , that is million.

SLDB annual Sales and Income evolution

Quarterly financial results

Reported quarter income marked $-21.92 million with a profit margin of . Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, Solid sales marked a neutral movement and stayed stable a nan%. Looking back to recent quarterly results, Solid Biosciences posted 5 positive quarters in a row.
SLDB quarterly Sales and Income evolution

Solid ownership

When you are planning to invest in a stock, it's worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Solid Biosciences, 34.71% of all outstanding shares are owned by its staff.

In case of Solid stock, 77.40% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for SLDB stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Solid Biosciences:

Market cap$215.6 M
Total shares35.4 M
Float shares11.1 M
  - Institutional holdings (%)77.4%
  - Insider holdings (%)34.7%
Shares in short selling0.0%

Solid summary

Tuesday, May 21st, 2019
Day range$5.70 - $6.20
Previous close$5.81
Session gain4.82%
Average true range$0.78
50d mov avg$9.16
100d mov avg$14.15
200d mov avg$25.07
Daily pattern
Weekly pattern lb06a

Solid performance

To measure stock performance is always good to compare with competitors or related stocks. For Solid Biosciences, the comparison is made against .
SLDBSolid Biosciences-32.03%-80.76%-67.86%

Solid competitors

Unfortunately, we could not find any public company that could be defined as Solid Biosciences competitor. This doesn't mean Solid Biosciences does not have any competitor in the market, it's just we could not detected it.